<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749931</url>
  </required_header>
  <id_info>
    <org_study_id>CP-03-001</org_study_id>
    <nct_id>NCT00749931</nct_id>
  </id_info>
  <brief_title>MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery</brief_title>
  <acronym>Pivotal</acronym>
  <official_title>MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dune Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dune Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that addition of device use to a routine breast cancer
      tumor excision procedure is beneficial and assists the surgeon in correctly determining the
      extent of excision.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi-center, randomized, double arm study demonstrating the
      effectiveness of the device in adjunctive use for locating the tissue for additional excision
      following primary specimen excision. One arm is a &quot;Standard of Care&quot; (SOC) Control group and
      the other arm a &quot;Device+SOC&quot; group.In the &quot;Device +SOC&quot; group the surgeon will use the
      MarginProbe device on the tissue specimen removed during the surgical procedure.The surgeon
      will use the results derived from the device and other routine assessments to decide if it is
      necessary to remove some additional breast tissue.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Effectiveness Endpoint is a Measure of Intraoperative Success in Addressing Positive Margins as Detected by Permanent Pathology)by Additional Oriented Tissue Re-excision From the Surgical Cavity.</measure>
    <time_frame>two weeks after surgery</time_frame>
    <description>Tests the efficacy of the device to intra-operatively assess positive margins (superiority) - CSR is 'positive' when all positive margins, as detected by histology, on the main specimen addressed intra-operatively</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">664</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care arm - standard of care lumpectomy procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Device + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of the device in addition to the standard of care lumpectomy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MarginProbe</intervention_name>
    <description>Device use to assess margin status of the excised specimen surface.</description>
    <arm_group_label>Device + SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumpectomy</intervention_name>
    <description>Standard of care lumpectomy procedure</description>
    <arm_group_label>SOC</arm_group_label>
    <arm_group_label>Device + SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women histologically diagnosed with carcinoma of the breast

          2. Women with non-palpable malignant lesions, requiring image guided localization.

          3. Undergoing lumpectomy (partial mastectomy) procedure.

          4. Age 18 years or more

          5. Signed ICF

        Exclusion Criteria:

          1. Multicentric disease (histologically diagnosed cancer in two different quadrants of
             the breast)

          2. Bilateral disease (diagnosed cancer in both breasts)

          3. Neoadjuvant systemic therapy

          4. Previous radiation in the operated breast

          5. Prior surgical procedure in the same breast

          6. Implants in the operated breast

          7. Pregnancy

          8. Lactation

          9. Participating in any other investigational study for either drug or device which can
             influence collection of valid data under this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanir M. Allweis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moshe Carmon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tami Karni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harefeh Medical Center, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alison Estabrook, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Roosevelt, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Freya Schnabel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Clinical Cancer Center, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rache M. Simmons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheldon M. Feldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center, NY, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark A. Gittelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breast Care Specialist, Allentown, Pennsylvania, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Friedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Health Srvices, Baltimore, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristen L. Fernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franklin Square Hospital Center, Baltimore, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawna C. Willey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University Hospital, Washington, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorraine Tafra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anne Arundel Medical Center, Annapolis, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Lane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCIrvine Medical Center, California, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jay Harness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph Hospital, California, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice Police, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pacific Breast Care, California, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dennis R. Holmes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South California, California, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Karlan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars Sinai Hospital, California, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Akbari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Frazier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bryn Mawr Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa E. Guerra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOAG Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan K. Boolbol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Medical Center, NY, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Breast Care</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOAG Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92658-6100</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCIrvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Services</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Square Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New-York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breast Care Center</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Hospital Center</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haddasah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dunemedical.com</url>
    <description>Dune Medical Devices official web site</description>
  </link>
  <results_reference>
    <citation>Schnabel F, Boolbol SK, Gittleman M, Karni T, Tafra L, Feldman S, Police A, Friedman NB, Karlan S, Holmes D, Willey SC, Carmon M, Fernandez K, Akbari S, Harness J, Guerra L, Frazier T, Lane K, Simmons RM, Estabrook A, Allweis T. A randomized prospective study of lumpectomy margin assessment with use of MarginProbe in patients with nonpalpable breast malignancies. Ann Surg Oncol. 2014 May;21(5):1589-95. doi: 10.1245/s10434-014-3602-0. Epub 2014 Mar 5.</citation>
    <PMID>24595800</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2008</study_first_submitted>
  <study_first_submitted_qc>September 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <results_first_submitted>May 26, 2014</results_first_submitted>
  <results_first_submitted_qc>May 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2014</results_first_posted>
  <last_update_submitted>May 26, 2014</last_update_submitted>
  <last_update_submitted_qc>May 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IDC, DCIS, ILC</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care (SOC)</title>
          <description>Standard of Care arm - standard of care lumpectomy procedure
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
        <group group_id="P2">
          <title>Device + (Standard of Care) SOC</title>
          <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
        <group group_id="P3">
          <title>Roll-in</title>
          <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="298"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="298"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care (SOC)</title>
          <description>Standard of Care arm - standard of care lumpectomy procedure
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
        <group group_id="B2">
          <title>Device + (Standard of Care) SOC</title>
          <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="298"/>
            <count group_id="B2" value="298"/>
            <count group_id="B3" value="596"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="11.1"/>
                    <measurement group_id="B2" value="60.3" spread="11.4"/>
                    <measurement group_id="B3" value="60.3" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Effectiveness Endpoint is a Measure of Intraoperative Success in Addressing Positive Margins as Detected by Permanent Pathology)by Additional Oriented Tissue Re-excision From the Surgical Cavity.</title>
        <description>Tests the efficacy of the device to intra-operatively assess positive margins (superiority) - CSR is 'positive' when all positive margins, as detected by histology, on the main specimen addressed intra-operatively</description>
        <time_frame>two weeks after surgery</time_frame>
        <population>The Analysis Set for evaluating intraoperative assessment consisted of patients with at least one histologically positive margin on main lumpectomy specimen (&quot;PSS&quot; – Positive specimen subjects)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Standard of Care arm - standard of care lumpectomy procedure
Lumpectomy: Standard of care lumpectomy procedure</description>
          </group>
          <group group_id="O2">
            <title>Device + (Standard of Care) SOC</title>
            <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Effectiveness Endpoint is a Measure of Intraoperative Success in Addressing Positive Margins as Detected by Permanent Pathology)by Additional Oriented Tissue Re-excision From the Surgical Cavity.</title>
          <description>Tests the efficacy of the device to intra-operatively assess positive margins (superiority) - CSR is 'positive' when all positive margins, as detected by histology, on the main specimen addressed intra-operatively</description>
          <population>The Analysis Set for evaluating intraoperative assessment consisted of patients with at least one histologically positive margin on main lumpectomy specimen (&quot;PSS&quot; – Positive specimen subjects)</population>
          <units>percentage of participants analyzed</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="71.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Re-excision Lumpectomy Procedures Due to Positive Margin on Main Specimens</title>
        <time_frame>Up to 2 months post-surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SOC)</title>
            <description>Standard of Care arm - standard of care lumpectomy procedure
Lumpectomy: Standard of care lumpectomy procedure</description>
          </group>
          <group group_id="O2">
            <title>Device + (Standard of Care) SOC</title>
            <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
          </group>
        </group_list>
        <measure>
          <title>Re-excision Lumpectomy Procedures Due to Positive Margin on Main Specimens</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="298"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Fisher Exact</method>
            <param_type>Relative reduction</param_type>
            <param_value>.47</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 months post-surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care (SOC)</title>
          <description>Standard of Care arm - standard of care lumpectomy procedure
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
        <group group_id="E2">
          <title>Device + (Standard of Care) SOC</title>
          <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
        <group group_id="E3">
          <title>Roll-in</title>
          <description>Use of the device in addition to the standard of care lumpectomy procedure.
MarginProbe: Device use to assess margin status of the excised specimen surface.
Lumpectomy: Standard of care lumpectomy procedure</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="298"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="298"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="298"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Manager</name_or_title>
      <organization>Dune Medical Devices</organization>
      <phone>+97246178000</phone>
      <email>shiri@dunemedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

